Epstein-Barr virus latent membrane protein 1-derived peptide epitopes presented on MHC class I molecules (LMP1-pMHC)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is a critical oncogenic protein that functions as a constitutively active mimic of the CD40 receptor, driving cell proliferation and survival in EBV-associated malignancies (UniProt P03230). While LMP1 is an intracellular protein, its degradation products are processed and presented on the cell surface as peptide epitopes bound to MHC class I molecules, such as HLA-A*02:01 (PubMed: 25239446). These LMP1-pMHC complexes serve as specific targets for advanced immunotherapies, including T-cell receptor (TCR) engineered T cells and TCR-like antibodies, which can recognize and eliminate cells expressing viral antigens (PubMed: 30552148). This targeting strategy is particularly relevant for Type II and Type III EBV latency-associated cancers, such as nasopharyngeal carcinoma and Hodgkin lymphoma, where LMP1 is consistently expressed. Therapeutic interventions like Tabelecleucel utilize the recognition of these epitopes by cytotoxic T lymphocytes to treat EBV-related lymphoproliferative diseases (Ebvallo Summary of Product Characteristics). However, challenges remain regarding the potential for off-target cross-reactivity with similar human self-peptides and the downregulation of MHC molecules by tumor cells as a mechanism of immune escape (PubMed: 28103464).

Other names

LMP1 peptide-MHC complexEBV LMP1 epitopesHLA-presented LMP1 peptidesLMP1-HLA-A*02:01 complexLatent membrane protein 1 antigen

Targeting of the peptide-MHC complex by engineered or endogenous T-cells leads to the directed lysis of EBV-infected or transformed cells through the release of perforin and granzymes.